According to Nielsen and Wolters Kluwer, the OTC oral/nasal allergy market grew by about 30% in the first half of 2008, compared with same period in 2007.

Like Zyrtec OTC, PL Cetirizine had rapid uptake, accounting for approximately one-third of the OTC cetirizine market’s patient volume during the spring 2008 allergy season.  Zyrtec OTC accounted for the remaining two-thirds of the cetirizine market’s patient volume, Nielsen and Wolters Kluwer reported.

Approximately 30% to 50% of PL Cetirizine’s business came from patients who are new to the allergy market, according to Nielsen and Wolters Kluwer.  Another 40% of PL Cetirizine’s patients switched from another medication — most notably, Private Label Loratidine, Claritin OTC, and Zyrtec OTC.

Like many OTC products, which typically lure consumers with lower prices, PL Cetirizine has offered patients cost savings.  Patients who switched to PL Cetirizine from any prescription or OTC allergy medication saved $1.56, on average, according to Nielsen and Wolters Kluwer.  Those switching from Zyrtec Rx saved an average of $6.19.

In the first six months following its launch (January to June 2008), Zyrtec OTC shook up prescription and OTC allergy medication markets in the U.S.   Prescription allergy drug sales declined sharply, while over-the-counter allergy drug sales increased significantly.

By June 2008, prescription sales of Zyrtec had declined to nearly negligible levels.  Meanwhile, the OTC form quickly gained acceptance, capturing almost one-quarter of the OTC allergy medication market — the same share held by market leaders Benadryl and Claritin OTC, which have been available for several years. 

More than 60% of Zyrtec OTC’s business came from patients who had not used an allergy product in the previous two years, or who use Zyrtec OTC concomitantly with other products, according to Nielsen and Wolters Kluwer. 

Another 40% of Zyrtec OTC buyers switched from a competing prescription or OTC allergy medication.  Among this group, 84% of patients switched specifically from another OTC product.

Perhaps most surprisingly, while OTC products typically lure consumers with their cost savings, 68% of patients who switched to Zyrtec actually spent more than they did on their prior prescription or OTC allergy treatment, Nielsen and Wolters Kluwer found. 

Nielsen and Wolters Kluwer tracked the market transition behavior of 57,000 consumers vis-à-vis Zyrtec over a 30-month timeframe.

Read the related white paper.

Learn more about prescription-to-OTC pharma trends: attend Nielsen’s Webinar, “Revealing the Landscape of Rx-to-OTC Switching,” on November 18, 2008.

According to NielsenHealth, U.S. households with at least one obese member spend 9% more than the average American household on over-the-counter medications, 10% more on health and beauty care products, and almost 17% more on total medications and remedies. 

Obesity sufferers tend to live in low-income households, with incomes of less than $20,000/year, and are more likely to be middle-aged (45 to 64 years old).  These households tend to be located in less affluent towns and rural areas (39%). 

On average, households with obese members are more willing to buy generic or private label brands.  They also purchase 20% more low calorie carbonated soft drinks than the average U.S. household, and are more willing to buy prescription drugs from outside the U.S. in order to save money.

As marketers turn their attention to this once-overlooked demographic, Americans are also turning an eye inward to examine the causes of the country’s obesity epidemic.

According to a 2008 Nielsen survey cited in the November issue of Nielsen’s “Consumer Insight” online newsletter, 81% of U.S. consumers “agreed” or “strongly agreed” that weight gain can be attributed to eating too much and not exercising enough. 

What’s more, 68% of consumers “disagreed” or “disagreed strongly” with the statement that they cannot find healthy food in their grocery store.

Consumers also told Nielsen they hold food companies and their advertising partially responsible for America’s obesity epidemic.  Almost three-quarters of consumers believe that advertising by food companies encourages people to eat less-healthy food, and that these companies should provide healthier food.  In comparison, consumers did not identify the fast-food industry as a major player in the obesity blame game.

Learn more about U.S. consumers’ perceptions of obesity.

Read more about marketers’ efforts to reach obese consumers in the November issue of Nielsen’s “Consumer Insight” online newsletter.

Read coverage of Nielsen’s findings in Adweek.